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Katherine Gass1, Madsen V. E. Beau de Rochars2, Daniel Boakye3, Mark Bradley4, Peter U. Fischer5, John
Gyapong6, Makoto Itoh7, Nese Ituaso-Conway8, Hayley Joseph9, Dominique Kyelem1, Sandra J. Laney10,
Anne-Marie Legrand11, Tilaka S. Liyanage12, Wayne Melrose9, Khalfan Mohammed13, Nils Pilotte10,
Eric A. Ottesen1, Catherine Plichart11, Kapa Ramaiah14, Ramakrishna U. Rao5, Jeffrey Talbot1, Gary J.
Weil5, Steven A. Williams10, Kimberly Y. Won15, Patrick Lammie15*
1 Lymphatic Filariasis Support Center, The Task Force for Global Health, Decatur, Georgia, United States of America, 2 Hopital Ste. Croix, Leogane, Haiti, 3 Noguchi
Memorial Institute for Medical Research, University of Ghana, Legon-Accra, Ghana, 4 Global Community Partnerships, GlaxoSmithKline, London, United Kingdom,
5 Washington University School of Medicine, St. Louis, Missouri, United States of America, 6 Research and Development Division, Ghana Health Service, Accra, Ghana,
7 Department of Parasitology, Aichi Medical University School of Medicine, Nagakute, Aichi-ken, Japan, 8 National Program for Elimination of Lymphatic Filariasis, Ministry
of Health, Funafuti, Tuvalu, 9 Lymphatic Filariasis Support Centre, School of Public Health, Tropical Medicine and Rehabilitation Sciences, James Cook University,
Townsville, Queensland, Australia, 10 Department of Biological Sciences, Smith College, Northampton, Massachusetts, United States of America, 11 Institut Louis Malardé,
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Abstract
Successful mass drug administration (MDA) campaigns have brought several countries near the point of Lymphatic Filariasis
(LF) elimination. A diagnostic tool is needed to determine when the prevalence levels have decreased to a point that MDA
campaigns can be discontinued without the threat of recrudescence. A six-country study was conducted assessing the
performance of seven diagnostic tests, including tests for microfilariae (blood smear, PCR), parasite antigen (ICT, Og4C3) and
antifilarial antibody (Bm14, PanLF, Urine SXP). One community survey and one school survey were performed in each
country. A total of 8,513 people from the six countries participated in the study, 6,443 through community surveys and
2,070 through school surveys. Specimens from these participants were used to conduct 49,585 diagnostic tests. Each test
was seen to have both positive and negative attributes, but overall, the ICT test was found to be 76% sensitive at detecting
microfilaremia and 93% specific at identifying individuals negative for both microfilariae and antifilarial antibody; the Og4C3
test was 87% sensitive and 95% specific. We conclude, however, that the ICT should be the primary tool recommended for
decision-making about stopping MDAs. As a point-of-care diagnostic, the ICT is relatively inexpensive, requires no
laboratory equipment, has satisfactory sensitivity and specificity and can be processed in 10 minutes—qualities consistent
with programmatic use. Og4C3 provides a satisfactory laboratory-based diagnostic alternative.
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The decision to stop MDA is complicated and a variety of tools
have been suggested to guide the decision [4]. The first step is to
define the parameter(s) that will be measured and the best
diagnostic tool for assessing it. At least seven diagnostic tests are
currently available for detecting indicators of LF exposure and
infection. Selection of the best diagnostic test for use in stoppingMDA decisions requires consideration of each test’s accuracy,
technical requirements, programmatic feasibility and reliability
[5], as well as confidence in test performance, especially since there
is no single gold standard test for LF (see Discussion). Next,
following the selection of a preferred diagnostic tool for defining

Introduction
In 2000 the Global Programme to Eliminate Lymphatic Filariasis
(GPELF) was launched, providing antifilarial drugs to millions of
people through mass drug administration (MDA) programs. During
the GPELF’s first nine years over 2.6 billion treatments of antifilarial
drugs were given to people in 48 countries through MDA programs
[1]. The success of the GPELF has led to dramatic reductions of
both microfilaremia and antigenemia levels in countries that have
completed multiple rounds of MDA [2]; the challenge now is to
determine when it is most appropriate to stop MDA [3].
www.plosntds.org
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activities, convenience sampling was used to select both communities and schools. However, selection of participants within each
site was conducted randomly whenever possible.

Author Summary
Lymphatic filariasis (LF), a mosquito-borne parasitic
disease, is a candidate for elimination largely because of
the success of mass drug administration (MDA) campaigns,
in which entire at-risk populations are given a once-yearly
regimen of single-dose treatment with two medications.
As a result, a diagnostic tool is needed to determine when
the prevalence of LF has fallen below the threshold for
sustained transmission so that MDA programs can be
stopped. To determine the best diagnostic tool available, a
multi-country study was conducted to assess the performance of seven diagnostic tests on a panel of patient
specimens. The selection of the most effective diagnostic
test was based on an evaluation of each test’s accuracy,
technical requirements, programmatic feasibility and
reliability, as well as confidence in test performance. This
study found advantages and disadvantages to each test.
Based on the data and experiences it was determined that
the ICT test, a point-of-care rapid card test, is the preferred
diagnostic tool for use in defining the end-point of MDA,
although the Og4C3 test provides a suitable laboratorybased alternative.

Standard Operating Procedures
A workshop with all the investigators was held in Atlanta, GA to
establish the study protocols and Standard Operating Procedures
(SOP) [7] prior to the start of the study. For each country, a team
of experienced investigators traveled to the study site to train the
local team on data collection methods and laboratory procedures
in accordance with the SOP.

Demographic Data Collection
All information on the participants was collected using
handheld personal digital assistants (PDA) (Dell Axim X50 or
X51) that eliminated the need for paper records. Unique
identifiers were printed on labels which provided visual identification of the number as well as barcodes acquired by a BluetoothH
scanner (CHS 7p v.1, Socket Mobile) to facilitate specimen
management. The PDAs were equipped with GPS devices
(GlobalSat, City of Industry, CA, USA) and GPS coordinates
were captured at each house and school visited. A questionnaire
was administered to collect demographic information that
included age, gender, bednet use, self-reported filarial disease
status and compliance with the most recent MDA. Multiple teams
could register households at the same time, and data collected
could be synchronized in the field to create one master database.
Each night all data were uploaded to a field laptop and a backup
of the data was created on an external drive. Data were
electronically transmitted in the form of encrypted excel files to
the central analysis database at the Task Force for Global Health
(Atlanta, GA).

the end-point of MDA, the question of how best to sample the
population must be resolved.
In response to these and other challenges, this study was
planned to evaluate diagnostic tools to assess MDA program
success by standardizing the tools now available, comparing their
effectiveness in demonstrating the interruption of LF transmission,
and selecting the most effective for deciding when MDA can be
suspended [6]. A large multi-country study was conducted in
2007–2008 to compare the effectiveness of seven available
diagnostic tests for detecting evidence of Wuchereria bancrofti
infection or transmission following multiple rounds of MDA, in
settings where infection prevalence was likely to be low. The goal
of the study was to select the best diagnostic tool(s) that would
allow for definition of program end-points that will maximize the
likelihood that LF transmission has been interrupted. Such a tool(s)
would be the cornerstone of programmatic decision-making.

Blood and Urine Collection
All field sample collections and field and laboratory tests were
conducted according to the SOP. Blood and urine samples were
collected 6–24 months following the last MDA. The periodicity of
W. bancrofti required that blood collection in the community
surveys be performed during the peak hours of microfilaremia
(during daytime hours for French Polynesia and Tuvalu and
between 10 pm and 2 am in the remaining countries where the
parasite was nocturnally periodic). In the areas with nocturnal
periodicity, collection teams had the option of registering
households during the day or night. Teams that registered
households during the day later returned in the evening to take
the blood samples. Approximately 0.3–0.4 ml of blood was
collected by finger prick from each participant into an EDTA
coated blood collection tube and stored in coolers overnight before
assays were performed the next day in the field laboratory. Up to
six diagnostic assays were performed (with the exception of Ghana,
which conducted up to five assays). Three of the assays were
conducted in the field laboratory: blood smear (MF), ICT
(Immunochromatographic test, Binax, Scarborough, ME), and
the PanLF Rapid (MBDr, Selangor, Malaysia). The one exception
to this was French Polynesia where the blood smear, ICT and
PanLF assays were processed at the Institut Louis Malardé. The
Bm14 antibody detection and Og4C3 antigen detection assays
were conducted in five reference laboratories (see Table 1) and the
PCR (Polymerase Chain Reaction) tests were conducted at Smith
College in Northampton, MA, USA.
For school participants, four diagnostic assays were performed:
two conducted on site (ICT and PanLF) and two conducted in
reference laboratories (Bm14 and Og4C3). Because microfilaremia

Methods
Site Selection
Studies were performed in French Polynesia, Ghana, Haiti, Sri
Lanka, Zanzibar (United Republic of Tanzania) and Tuvalu,
representing a broad diversity of settings in which LF is present.
The study sites were believed to have low residual microfilaremia
prevalence rates in the range of 0.5–2% following at least five
rounds of MDA [7].

Participant Selection
One community survey and one school survey were performed
in each country. Community surveys sampled residents of selected
households between the ages of 3 and 80. School surveys were
performed in primary schools that serve children in the same
villages as those selected for the community surveys. First and
fourth year students (approximately 6 and 10 years old,
respectively) were selected for inclusion in the school surveys.
Children from the school survey were excluded if they had already
been included in the community survey. Since the primary
objective of this first phase of research was not to assess program
end-points in the specific study sites, but rather to compare test
effectiveness in the same groups of individuals late in program
www.plosntds.org
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Table 1. Laboratory locations of diagnostic tests.

Bm14

PanLF

Urine SXP

ICT

Og4C3

Blood Smear

PCR*

French Polynesia

ILM

ILM

Aichi

ILM

ILM

ILM

Smith

Ghana

Noguchi

–

–

Field lab

Noguchi

Field lab

Smith

Haiti

CDC

Field lab

Aichi

Field lab

CDC

Field lab

Smith

Sri Lanka

Wash U.

Field lab

–

Field lab

Wash U.

Field lab

Wash U.

Tuvalu

Wash U.

Field lab

Aichi

Field lab

Smith

Field lab

Smith

Zanzibar

Smith

Field lab

Aichi

Field lab

Smith

Field lab

Smith

Aichi = Aichi Medical University (Japan).
CDC = Centers for Disease Control and Prevention (USA).
Field Lab = in-country laboratory created, or in use, by field team.
ILM = Institut Louis Malarde (French Polynesia).
Noguchi = Noguchi Memorial Institute for Medical Research (Ghana).
Smith = Smith College (USA).
Wash U = Washington University in St. Louis, Missouri (USA).
*Based on 10 ml blood specimen.
doi:10.1371/journal.pntd.0001479.t001

per disk), dried and stored until shipped to participating
laboratories for further testing.
Both the ICT and PanLF tests were conducted at the schools
and blood was spotted onto filter paper disks. All field test results
were entered into the PDA immediately and subsequently
uploaded to the field laptop each night.

levels were not assessed in the school surveys, blood collection
occurred during the day at the time of registration.
Urine cups were labeled and distributed at the time of
enrollment, and each participant was asked to provide a urine
sample (with the exception of those in Ghana and Sri Lanka). In
the field laboratory, approximately 5 ml of urine was transferred
into a smaller vial and sodium azide (0.1%) was added as a
preservative [8]. Urine vials were shipped to Aichi Medical
University (Nagoya, Japan) for anti-filarial antibody testing using
the W. bancrofti SXP recombinant antigen. Table 2 summarizes the
tests by: survey, specimen, test type, and target detected.

Laboratory Tests
Three laboratory assays were performed on the specimens, all of
which were previously validated against non-endemic samples.
One bloodspot (10 ml) was used for an enzyme linked immunosorbent assay (ELISA) to determine anti-filarial antibody reactivity
to the recombinant antigen Bm14 (Cellabs, Sydney, Australia).
Bloodspots were eluted overnight at 4uC and processed the
following day according to the agreed SOP. Three dried
bloodspots (3610 ml) were used to measure quantitative filarial
antigen levels by the Og4C3 ELISA (TropBio, Townsville,
Australia). Bloodspots were eluted overnight at 4uC and boiled
the next day. Boiled samples were centrifuged and supernatants
were incubated overnight on a 96-well microtiter plate pre-coated
with an Og4C3 monoclonal capture antibody. Plates were
processed the next day. One bloodspot (10 ml) was used for PCR
to detect the presence of parasite DNA. Bloodspots were pooled
into groups of 10 individuals for initial testing. DNA was extracted
using the QIAGEN DNeasy kit (Valencia, CA, USA) and analyzed
by real-time PCR (qPCR) [9]. If a pool was positive, each sample

Field Tests
Blood films were used to determine MF levels in the
communities. Sixty microliters of blood was streaked onto a glass
slide (3 lines620 ml), stained with Giemsa and read in the field
laboratories. Filarial-antigen status was determined by ICT (Binax,
Scarborough, ME, USA). EDTA anti-coagulated blood was used
and the test was performed according to manufacturer’s
instructions. Antigen positive individuals were offered treatment
with albendazole plus DEC or ivermectin. Anti-filarial antibody
status was determined using the PanLF Rapid (MBDr, Selangor,
Malaysia) cartridge test. EDTA anti-coagulated blood (35 ml) was
placed on the sample pad and the test was performed according to
manufacturer’s instructions. The remaining blood was spotted
onto two filter paper disks (TropBio, Townsville, Australia) (60 ml
Table 2. Diagnostic test characteristics.

Test Name

Surveys Used

Specimen Type

Test Type

Target Detected

Bm14

Community & School

Bloodspot

ELISA

Antifilarial antibody

PanLF

Community & School

Blood

Rapid cassette test

Antifilarial antibody

Urine SXP

Community & School

Urine

ELISA

Antifilarial antibody

ICT

Community & School

Blood

Rapid card test

Filarial-antigen

Og4C3

Community & School

Bloodspot

ELISA

Filarial-antigen

Blood Smear

Community

60 ml Blood

Blood film

Microfilariae

PCR*

Community

10 ml Bloodspot

qPCR

Microfilariae

*Based on 10 ml blood specimen.
doi:10.1371/journal.pntd.0001479.t002
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guardian. Interviewers documented receipt of verbal consent for
all participants using handheld PDA devices. Finally, the Ethical
Review Committee in Zanzibar (Zanzibar Health/Medical Task
Force) approved the Zanzibar study protocol and work. For the
community all participants were given consent forms to sign while
for the school children parents/guardians of the children were
informed of the study through School Committee meetings and an
informed consent letter was handed over to them to be signed. In
addition to obtaining written consent from participants, interviewers documented receipt of consent for all participants using
handheld PDA devices.

that comprised the positive pool was tested individually using an
additional 10 ml bloodspot. Results for all laboratory tests were
entered into a standardized Microsoft ExcelH spreadsheet and sent
electronically to the Task Force for Global Health to be entered
into the analysis database.

Ethics Statement
The research proposal was submitted by the principal
investigators of each participating country to the local review
board, or in certain cases an outside review board, as deemed most
appropriate. All proposals were accepted by the respective review
boards before research took place. The US-based laboratories
analyzing results received an exemption from the IRBs, since all
specimens and results were de-linked from personal identifiers. All
subjects provided informed consent to participate in the study.
More detailed information regarding the IRB institution for each
country and the method for obtaining participant consent are
described below.
In French Polynesia, the Ethics Committee approved the
French Polynesian study protocol and work. A consent form was
read to all a subjects and written agreement of consent was
required from subjects in order to participate in the study. Assent
was obtained from children and a written consent was required
from their parent or guardian. In addition to obtaining written
consent from participants, interviewers documented receipt of
consent for all participants using handheld PDA devices. For
Ghana, the Noguchi Memorial Institute for Medical Research’s
Institutional Review Board approved the study protocol and work.
Informed written consents were obtained from all individuals 18
years of age and above. For individuals aged 6–17 years informed
assent was sought from all individuals, in addition to written
consent of the parent or responsible adult. In addition to obtaining
written consent from participants, interviewers documented
receipt of consent for all participants using handheld PDA devices.
The procedure was explained to all children 3–5 years of age, in
addition to written consent of the parent or designated guardian.
In Haiti the Centers for Disease Control IRB committee approved
an amendment to a previously approved study protocol. Informed
consent was obtained from each participant. The CDC IRB
granted the team the right to obtain oral consent (assent for
children of age 6 years or younger and consent of their parents)
because most participants were unable to read and the research
presented no more than minimal risk of harm to the subjects.
Interviewers documented receipt of verbal consent for all
participants using handheld PDA devices. In Sri Lanka both the
Washington University IRB and the Sri Lanka Ministry of Health
approved the study protocol and work. Both institutions
considered the survey to be public health practice (evaluation of
the national LF elimination program) and as a result did not
require formal IRB submission; waiver letters were obtained. Field
teams used consent scripts and obtained verbal consent (assent
from children). Participation by children required consent from at
least one parent plus assent from the child. The Washington
University IRB and Sri Lanka Ministry of Health both approved
the collection of verbal consent for the survey because the research
was deemed to present no more than minimal risk of harm to the
subjects. Interviewers documented receipt of verbal consent for all
participants using handheld PDA devices. For Tuvalu the human
research ethics committee at James Cook University approved the
protocol and study. The ethical review committee at James Cook
University granted the right to obtain verbal consent, as opposed
to written consent, for this study, as the study was considered to
present minimal risk of harm to the subjects. Assent was obtained
from children, along with verbal consent from their parent or
www.plosntds.org

Analyses
All data were compiled and managed using SQL server (2005,
Microsoft CorporationH) and imported to SASH v.9.2 (Statistical
Analysis System; North Carolina) for analyses. Unless otherwise
stated, all statistically significant associations were determined by
setting the probability of a Type I error at 5% (a = 0.05).
Univariate analyses of country, age, and gender were calculated
for all specimens with results reading ‘‘positive’’, ‘‘negative’’, and
‘‘indeterminate’’ (Tables 2 and Table 3). For all remaining
analyses results were limited to specimens testing ‘‘positive’’ or
‘‘negative.’’
While five of the seven diagnostic tests provided qualitative
(positive/negative) results, two provided quantitative results
(Og4C3 and Bm14) in the form of unit values. In order to
dichotomize these quantitative results, a cut-off value was defined
for the Og4C3 and Bm14 tests, independently, such that all results
with a unit value greater than the cut-off were considered
‘‘positive.’’ Receiver Operating Characteristic (ROC) curves were
used to determine the best cut-off values, by plotting ‘sensitivity’ by
‘1-specificity’ at various signal to cut-off ratios using SASH. ROC
analysis requires identifying clearly positive and negative specimens whose assay values can be applied to the analysis, but since
there is no true ‘gold standard’ for defining LF infection,
operational criteria based on multiple tests were used to define
these groups.
This manuscript followed the Standards for the Reporting of
Diagnostic accuracy studies (STARD) (Checklist S1).

Results
A total of 8513 people from the six countries participated in the
study; 6443 through the community surveys and the remaining
2070 through the school surveys (Table 3). Specimens from these
participants were used to conduct 47,110 diagnostic tests (Table 4).
Of the 47,110 tests performed, 7481 test results (15.9%) were
excluded from the subsequent analyses due to invalid or
indeterminate test results (Table 5). Among the excluded results
were all of the Bm14 tests for Sri Lanka, Tuvalu and Zanzibar
(4006 tests) due to changes in the performance of the commercially
manufactured kits. In addition to the Bm14, all of the PanLF and
blood smear results from Zanzibar (a total of 2,329 tests) were
excluded due to technical uncertainties affecting the quality of the
results. Diagrams describing the process by which participant
specimens were tested, excluded and classified for each of the
antibody, antigen and microfilariae tests are available in the
supplementary Texts S1, S2, and S3.
ROC curves were used to determine the unit value cut-point to
distinguish ‘positive’ and ‘negative’ results for the Og4C3 and
Bm14 tests. For the Og4C3 antigen assessment true positives were
defined as those individuals with positive specimens for either the
blood smear (MF) test or PCR (parasite DNA). True negatives
were defined as individuals with negative blood smears and PCR
4
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Table 3. Demographic information by country and survey location.

Location
Community

School

All

Measure

French
Polynesia

Ghana

Haiti

Sri Lanka

Tuvalu

Zanzibar

All Countries
25

Age (median)

33

17

17

26

39

24

Age (IQR)

16–48

10–40

10–28

13–40

25–50

14–41

13–43

Percent Male

48

43

41

49

47

39

44

Total Tested

1018

1107

999

1167

1124

1028

6443

Age (median)

7

7

7

7

9

9

7

Age (IQR)

7–10

6–10

6–10

6–10

7–10

6–10

6–10

Percent Male

50

49

49

63

48

48

51

Total Tested

365

359

323

310

357

356

2070

Age (median)

20

12

12

19

29

16

17

Age (IQR)

9–42

8–30

7–23

8–36

10–46

10–36

9–37

Percent Male

48

44

43

52

47

41

46

Total Tested

1383

1466

1322

1477

1481

1384

8513

doi:10.1371/journal.pntd.0001479.t003

results (both negative or one negative and the other not assessed),
plus a negative by ICT and a Bm14 antibody value ,18 units.
The resulting ROC plots provided strong evidence that the cut-off
for defining an Og4C3 positive result should be 34 units.
Determining the cut-point for the antibody assay Bm14, using
the ROC, was more problematic. An antibody response is the first
identifiable marker following exposure to filarial infection, it is
therefore impossible to define true-positive infections by the
presence of antibody. Assay sensitivity can be determined with
respect to microfilaremia or antigenemia; however, specificity
cannot be conceptually assessed (see Discussion). Indeed ROC
analysis for the Bm14 cut-off proved to be inconclusive. Instead it
was decided that positivity and negativity be discriminated on the
basis of Optical Density values, based on a standard curve run for
each test plate [7]. Therefore, the value of 64 units was used as the
cut-off, which follows the manufacturer’s recommendations and is
consistent with the available ROC findings.
As shown in Table 6, 22.8% of participants’ specimens had
valid results for the full battery of seven tests while almost two
thirds of participant specimens had valid results for five or more
tests. Bm14 had the highest prevalence of positive results, with
country-specific prevalence reaching 53.1% in Haiti (Table 7).
The PanLF antibody and urine SXP antibody tests had the second
and third highest positivity, with the highest prevalence found in

Haiti (41.5%, Table 7) and French Polynesia (22.5%, Table 7),
respectively. Across all countries, 17.5% of specimens were
positive by PanLF and 20.5% by urine SXP (Table 8). At the
country-level, antigen positivity ranged from around 0.5% in Sri
Lanka to over 21.2% in Haiti (Table 7), while overall
approximately 9% were positive by ICT and 8% by Og4C3
(Table 8). The tests with the least number of positive results were
PCR and blood smear, with approximately 1.5% of specimens
testing positive overall, though again positivity varied at the
country-level.
Though the overall levels of positivity were similar within targets
of detection (antibody, antigen or microfilaremia), at the individual
level the tests differed significantly. A comparison of the blood
smear and PCR results using McNemar’s test, matched on
participant, found a significant difference between the two tests
(p = 0.024). Likewise, a comparison of the ICT and Og4C3 results
found the two antigen tests to be significantly different (p = 0.003).
The prevalence of antifilarial antibodies differed significantly
(p,0.0001) between Bm14, PanLF, and urine SXP tests. The
results from all seven diagnostic tests indicated a significant ageprevalence trend of increasing positivity with age (p,0.0001)
(Table 8). Of the diagnostic tests, the Bm14 and PanLF were found
to be the most reactive in the youngest age groups. In the school
studies, which focused on a comparison of 5–7 and 9–11 year olds,

Table 4. Specimens and tests performed by country of origin.

Test Name

French Polynesia Ghana

Haiti

Sri Lanka

Tuvalu

Zanzibar

All Countries

PanLF

1372

0

1269

1399

1448

1377

6865

Bm14

1329

1159

1214

1463

1245

1298

7708

Urine SXP

1268

0

1285

0

955

1366

4874

ICT

1359

1372

1266

1449

1455

1316

8217

Og4C3

1355

1355

1179

1432

1333

1126

7780

PCR*

1005

972

893

1161

1063

886

5980

Blood Smear

713

1081

882

1043

1015

952

5686

TOTAL

8401

5939

7988

7947

8514

8321

47110

*Based on 10 ml blood specimen.
doi:10.1371/journal.pntd.0001479.t004
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Table 5. Invalid or indeterminate test results by country (excluded from remaining analyses).

Test

French Polynesia Ghana

Haiti

Sri Lanka

Tuvalu

Zanzibar

All Countries

PanLF

66

–

48

435

382

1377

2308

Bm14

0

0

0

1463

1245

1298

4006

Urine SXP

0

–

0

–

0

0

0

ICT

25

119

33

1

7

30

215

Og4C3

0

0

0

0

0

0

0

PCR*

0

0

0

0

0

0

0

Blood Smear

0

0

0

0

0

952

952

TOTAL

91

119

81

1899

1634

4009

7481

Note: These test results make up 15.9% of the total (47,110) results.
*Based on 10 ml blood specimen.
doi:10.1371/journal.pntd.0001479.t005

(i.e. few people had filarial antigenemia in the absence of a
detected antibody response). Bm14 had the poorest negative
concordance with the remaining tests in the school surveys; only
66–72% of those specimens negative by PanLF, urine SXP, ICT
or Og4C3 were also negative by Bm14. However, since antibody
tests are expected to be the most sensitive at detecting exposure to
LF, it is possible that specimens negative for antigenemia would
still be ‘true positive’ for Bm14 antibody.
The negative concordance of the antigen tests with the antibody
tests was somewhat less in the community survey compared to the
school survey, with 90–97% of antibody negative specimens (by
Bm14 or PanLF) also testing antigen negative (by ICT or Og4C3)
(Table 12). The pair-wise specificity of Bm14 was similarly low in
the community survey, as compared to the school survey, with
Bm14 identifying as negative approximately two thirds of results
that were negative by any of the remaining tests. Comparatively
PanLF identified as negative 74–94% of results that were negative
by the remaining six tests.
In the absence of a true gold standard test for LF infection,
operational definitions of positive and negative gold standards
were used to calculate sensitivity and specificity. To measure
sensitivity, ‘true positives’ were defined as being either blood smear
or PCR positive. The sensitivity of the assays therefore relates to
the sensitivity for detecting microfilaremic infections, a measure of
justifiable interest to the global LF elimination program, since
microfilariae are required to transmit infection. It is more difficult
to define a gold standard for specificity of assays since it is
recognized that exposure alone can convert individuals to positiveantibody status. Consequently, ‘true negatives’ for antibody tests
cannot be defined based on the results of the antigen and parasite
tests, making it impossible to calculate the specificity for the
antibody tests. Specificity of the antigen tests can be assessed if one
evaluates the ability of the antigen assays to identify individuals
who are amicrofilaremic and have no antibody evidence of
infection or exposure to infection. ‘True negatives’ for the antigen
tests were therefore defined based on negative blood smear and
PCR results (both negative or one negative and the other not
assessed) as well as negative results for both Bm14 and PanLF. It is
important to note that this was a conservative definition of antigen
specificity, as only antibody-negative individuals were eligible to be
considered ‘true negatives’ by the antigen tests (see Discussion).
Sensitivity and specificity of test performance was calculated
using the best-estimate gold standards as defined above. These
calculations were limited to French Polynesia, Ghana, and Haiti
due to missing values for Bm14 in the remaining countries.
Overall, the ICT test was found to be 76% sensitive at detecting

there were no significant differences in test results between the two
age groups, and the results were subsequently pooled.
The test concordance tables (Tables 9, 10, 11,12) record the
pair-wise comparisons of test results within the school and
community surveys. The resulting estimates can be considered
the pair-wise sensitivity of the test. In the school survey, Og4C3
picked up 57% of the ICT positive results, whereas ICT picked up
51% of the Og4C3 positive results (Table 9). Among the antibody
tests, Bm14 identified 90% of the positive PanLF results, whereas
PanLF only identified 41% of the Bm14 results. These differences
reflect the greater sensitivity of the ELISAs compared to the rapid
tests. The urine SXP tests consistently identified about a quarter of
the positive results from the remaining four tests.
In the community survey, Og4C3 detected 87% and 91% of the
blood smear and PCR positive results, respectively, while ICT
detected 80% and 78% of the blood smear and PCR positive
results, respectively (Table 10). The positive concordance between
ICT and Og4C3 ranged from 53% (ICT positives testing positive
by Og4C3) to 62% (Og4C3 positives testing positive by ICT). Of
the microfilaremic individuals (positive by blood smear) only 61%
were positive by a 10 ml PCR. Conversely 75% of PCR positive
individuals were also positive by blood smear. Among the antibody
tests, Bm14 identified 90% of individuals positive by PanLF or
urine SXP.
Negative test concordance in the school survey (Table 11)
revealed that 98% of antibody negative individuals (by Bm14 or
PanLF) also tested negative by the antigen tests (ICT or Og4C3)
Table 6. Number of valid* tests performed on participants
specimens.

No. of tests performed No. of participants %

Cumulative %

0

2

0

0

1

59

0.7

0.7

2

257

3.0

3.7

3

605

7.1

10.8

4

1980

23.3

34.1

5

2270

26.7

60.8

6

1397

16.4

77.2

7

1943

22.8

100.0

*Note: This does not include the 7,481 invalid or indeterminate tests.
doi:10.1371/journal.pntd.0001479.t006
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Table 7. Prevalence of positive results by test and country.

Bm14

PanLF

Urine SXP

ICT

Og4C3

Blood Smear

PCR (10 ml)

French Polynesia

46.0%

14.0%

22.5%

9.0%

6.4%

3.8%

2.2%

Ghana

9.9%

–

–

6.7%

8.9%

2.1%

0.8%

Haiti

53.1%

41.5%

18.5%

21.2%

18.8%

4.3%

4.0%

Sri Lanka

–

7.2%

–

3.0%

0.5%

0.4%

0.2%

Tuvalu

–

25.2%

20.1%

5.0%

4.9%

0.1%

0.3%

Zanzibar

–

–

20.9%

8.1%

8.17%

–

0.8%

doi:10.1371/journal.pntd.0001479.t007

requirements, so the selection of the diagnostic tool to use is of
paramount importance. Accuracy, programmatic feasibility,
testing requirements, time and cost must all be factored into the
evaluation of the potential diagnostic tools [10]. The current study
arose in response to this challenge. A summary of the features and
performance of the seven diagnostic tests evaluated is presented in
the supporting table at the end of this paper (Table S1).
A common theme that emerges from this multi-country study is
that the majority of the tests did not perform as well as expected,
with regards to both accuracy and reliability. Though this finding
is disappointing, it is important to note that the study represents an
effectiveness trial, with the majority of the tests being conducted
under varying conditions on-site or in field laboratories by local
technicians. Though all the technicians were well-schooled, there
were differences in adherence to established protocols. Indeed, the
lessons learned with respect to test performance in this multicountry setting provide valuable insight and will hopefully lead to
future test improvements. Some common areas identified for
improvement across many of the tests include the need for
thorough training of test-readers and lab technicians, along with
simplification of logistical issues related to specimen storage,
shipping and linking with test results.
Another important concern identified was the need for
improved standardization and rigorous quality control of commercially manufactured tests and kits, a problem noted particularly with variability in the lots of commercial kits measuring
Bm14 antibodies (CELISA) and the TropBio Og4C3 antigen test.
In addition, with an increasing reliance on laboratory tests for
programmatic decision making, there is a critical need to provide

microfilaremic infections and 93% specific at identifying individuals negative for both microfilariae and antifilarial antibody
(Table 13). Using the same gold standard estimates, Og4C3 was
found to be 87% sensitive and 95% specific. Stratifying the results
by country revealed a high degree of variability in these estimates.
ICT sensitivity ranged from 61% in Ghana to 79% in Haiti and
French Polynesia, while ICT specificity ranged from 89% in Haiti
to 94% in Ghana. Similarly, the sensitivity of Og4C3 assays
ranged from 72% in Ghana to 93% in French Polynesia, while
Og4C3 specificity ranged from 92% in Ghana to 99% in French
Polynesia. It is important to note that a portion of the variability is
due to the relatively small sample sizes in the country-specific
results, caused by the gold standard criteria.
The sensitivity of the antibody tests at detecting microfilaremic
individuals was 81% for Bm14, 73% for PanLF and 55% for SXP
in urine (Table 14). Again, there was significant variability in these
estimates at the country level, with Bm14 sensitivity estimates
ranging from 50% in Ghana to 92% in French Polynesia. PanLF
sensitivity ranged from 50% in Tuvalu to 77% in French
Polynesia. Urine SXP sensitivity ranged from 32% in Haiti to
92% in French Polynesia. As with the antigen results, small sample
size due to the limited number of microfilaremic individuals, is
likely to account for some of the variability in the sensitivity
estimates.

Discussion
Deciding whether or not to stop MDA will be expensive and
laborious for countries because of both the sampling and testing

Table 8. Prevalence of positive results by age group (all countries).

Bm14
Age Group

% Pos.

PanLF
N

% Pos.

Urine SXP
N

% Pos.

ICT
N

% Pos.

Og4C3
N

% Pos.

N

Blood Smear

PCR*

% Pos.

% Pos.

N

N

0–5

30.2

199

15.9

270

5.3

227

6.3

384

5.3

356

0.7

310

0.6

313

06–10

31.8

1300

10.9

1770

6.5

1437

4.8

2507

4.8

2396

1.3

599

1.6

681

11–15

31.1

531

15.6

622

19.7

539

8.5

934

6.6

912

1.1

782

0.7

808

16–20

40.1

314

15.7

515

18.9

440

9.6

668

9.4

652

1.7

637

1.1

663

21–30

36.8

394

20.0

747

21.0

581

10.7

986

7.9

963

1.1

955

0.6

973

31–40

46.1

297

22.4

647

26.9

527

11.9

831

10.7

804

1.5

787

1.3

824

41–50

46.0

265

20.5

599

35.0

511

11.2

785

9.3

762

2.7

737

2.2

781

.50

50.3

402

28.7

691

42.8

612

11.3

954

11.2

935

2.4

882

1.9

942

TOTAL

37.0

3702

17.5

5861

20.5

4874

8.6

8049

7.6

7780

1.6

5686

1.3

5980

*Based on 10 ml blood specimen.
doi:10.1371/journal.pntd.0001479.t008
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Table 9. Positive-to-positive concordance in school survey.

COMPARISON TEST (Numerator)
INDEX TEST
(Denominator)

BM14

BM14
PanLF

120/133 (90%)

Urine SXP

38/42 (90%)

PANLFBC

URSXP

ICT

OG4C3

120/292 (41%)

38/283 (13%)

45/311 (14%)

53/310 (17%)

33/136(24%)
33/44 (75%)

ICT

45/61 (73%)

44/63 (69%)

16/66 (24%)

Og4C3

53/63 (84%)

54/64 (84%)

18/77 (23%)

44/145 (30%)

54/138 (39%)

16/69 (23%)

18/64 (28%)
42/74 (57%)

42/82 (51%)

Note: Fractions represent the number of positive results for each test (numerator) out of those that were positive by the index test (denominator). The results are of the
form: proportion (%). The number of positive index tests (denominator) changes by column because it only includes specimens with valid results by the comparison test
(numerator).
doi:10.1371/journal.pntd.0001479.t009

laboratories with standard operating procedures and assay controls
(e.g., samples for standard curves, positive and negative controls)
that can be used across all labs. Both efforts are needed to
guarantee that results generated across countries are comparable
and can be used to make robust program decisions.
Use of eluted filter paper blood spots rather than fresh serum in
this study might have contributed to the sub-optimal performance
of the Bm14 and Og4C3 ELISA tests. When this study was
planned, all investigators on the project agreed that filter paper
blood spots should be used for the ELISA tests. Multiple studies
have described the equivalence of the blood spot and serum
specimens for use in both the Bm14 and Og4C3 assays [11–14],
but since this analysis was conducted, other studies have suggested
that blood spots on filter paper might not perform as well as serum
in the Bm14 ELISA, and there has been a call for additional
studies to compare the two methods directly [15]. In the present
study, project laboratories found that blood spot eluates sometimes
produced variable and often high background OD values in the
Bm14 ELISA, so that data from these countries had to be rejected
(Table 5).
When evaluating the best diagnostic tool for programmatic
decision-making, the advantages of point-of-care tests are
appreciable. In this study, the anticipated advantages of lab-based
tests (i.e. better sensitivity and specificity) were outweighed by the
convenience, comparable accuracy, and ability to standardize

more easily the point-of-care tests. Given the challenges experienced with the lab-based tests (see Table S1) a point-of-care test
appears to be most preferable for assessments leading to a decision
on whether or not to stop MDA.
Taking these aspects into consideration, we conclude that the
ICT should be the primary tool recommended now for decisionmaking about stopping MDAs in areas with W. bancrofti infections.
As a point-of-care card test, the ICT is relatively inexpensive,
requires no laboratory equipment, and can be processed in
10 minutes, very consistent with programmatic use. As an antigen
test, a ‘‘positive’’ ICT result is indicative of the presence of adult
worms and the potential for ongoing transmission—arguably a
more appropriate measure for establishing an end-point for MDA
than antifilarial antibodies detecting exposure to infection.
Additional research is needed to determine whether antibody
tests are more appropriate for post-MDA surveillance.
One concern with the ICT that arose from this study was the
potential subjectivity involved in determining whether a weaklooking band indicates a positive or negative test. Fortunately,
improvements to training and training materials can be expected
to resolve some of this anxiety about the test’s use. Indeed, with
these improvements, the ICT appears as the diagnostic tool best
suited for use even in low-resource settings to determine when the
end-point for the MDA phase of the LF elimination program has
been reached.

Table 10. Positive-to-positive concordance in community survey.

COMPARISON TEST (Numerator)
INDEX TEST
(Denominator)

BM14

BM14

PANLFBC

URSXP

ICT

OG4C3

BLOOD SMEAR

PCR*

463/903 (51%)

386/905 (43%)

231/1015 (23%)

237/1033 (22%)

54/904 (6%)

55/1044 (5%)

370/714 (52%)

216/869 (25%)

220/841 (26%)

47/783 (6%)

47/854 (5%)

181/878 (21%)

193/829 (23%)

36/572 (6%)

36/853 (4%)

299/560 (53%)

70/468 (15%)

60/571 (11%)

76/397 (19%)

68/503 (14%)

PanLF

463/516 (90%)

Urine SXP

386/428 (90%)

370/582 (64%)

ICT

231/357 (65%)

216/384 (56%)

181/455 (40%)

Og4C3

237/323 (73%)

220/292 (75%)

193/367 (53%)

299/485 (62%)

Blood Smear

54/75 (72%)

47/65 (72%)

36/64 (56%)

70/88 (80%)

76/87 (87%)

PCR*

55/62 (89%)

47/60 (78%)

36/66 (55%)

60/77 (78%)

68/75 (91%)

52/85 (61%)
52/69 (75%)

Note: Fractions represent the number of positive results for each test (numerator) out of those that were positive by the index test (denominator). The results are of the
form: proportion (%). The number of positive index tests (denominator) changes by column because it only includes specimens with valid results by the comparison test
(numerator).
*Based on 10 ml blood specimen.
doi:10.1371/journal.pntd.0001479.t010
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Table 11. Negative-to-negative test concordance in school survey.

COMPARISON TEST (Numerator)
INDEX TEST
(Denominator)

BM14

BM14

PANLFBC

URSXP

ICT

OG4C3

334/347 (96%)

338/342 (98%)

628/644 (98%)

645/655 (98%)

566/577 (98%)

905/924 (98%)

880/890 (98%)

1012/1062 (95%)

921/980 (93%)

PanLF

334/506 (66%)

Urine SXP

338/583 (57%)

566/669 (84%)

ICT

628/894 (70%)

905/1006 (89%)

1012/1065 (95%)

Og4C3

645/902 (72%)

880/964 (91%)

921/967 (95%)

1740/1780 (97%)
1740/1772 (98%)

Note: Fractions represent the number of negative results for each test (numerator) out of those that were negative by the index test (denominator). The results are of
the form: proportion (%). The number of negative index tests (denominator) changes by column because it only includes specimens with valid results by the
comparison test (numerator).
doi:10.1371/journal.pntd.0001479.t011

This recommendation for the ICT test is not meant to
undervalue the relatively good performance of the Og4C3 test,
which was even more accurate than the ICT in identifying
microfilaremic individuals in this study. However, as a laboratorybased assay, the Og4C3 test provided some additional challenges,
including inconsistent product performance over time and quality
control in the testing laboratories. The Og4C3 and other ELISA
tests have performed well in research labs; our results and
experience with quality control have illustrated the potential
problems with translating these tools into an operational setting.
The Og4C3 provides a satisfactory diagnostic alternative that may
be appropriate in settings with well-equipped laboratories and the
ability to adhere to a quality assurance strategy.

not positive by blood smear and PCR but positive by Bm14 or
PanLF (n = 1737) were excluded from sensitivity and specificity
calculations for antigen tests, as they were neither ‘‘true positive’’
nor ‘‘true negative’’. It is important to note that such results are
biologically plausible, as they may be indicative of individuals
with increasing, but undetectable antigen levels, or they can
represent individuals who are no longer infected but still have
residual antifilarial antibodies. It is clear, though, that the
definitions used to establish test sensitivity and specificity are
imperfect because of the impossibility of defining a true gold
standard of infection.
The ROC analysis for determining Bm14 and Og4C3 cut-off
levels was also contingent upon the best-estimate criteria.
Therefore, any systematic errors resulting in misclassification of
the tests used in the best estimate gold standard have the potential
to influence this analysis. A sensitivity analysis was run, which
evaluated the suspected ICT false positives, as well as false positive
and false negative results with PCR and blood smear. The results
from the sensitivity analysis indicate that the sensitivity and
specificity of the tests, and conclusions drawn from this analysis, to
be robust under various scenarios of misclassification (data not
shown). For example, if all ICT-positive specimens with an Og4C3
quantitative result of ‘‘0’’ (N = 48) were considered ‘‘false
positives’’ and recoded as ICT-negative, the sensitivity and
specificity estimates would not change significantly.

Limitations and Areas of Future Research
The absence of a true gold standard test for LF infection was a
major limitation of this analysis. The need to define a bestestimate gold standard from the available tests further limited the
analysis since tests used in the definition cannot be assessed by the
same definition without entering into a tautology (an issue for
both PCR and blood smear). To measure the sensitivity and
specificity of the tests it was necessary to use the best-estimate
gold standard to define ‘‘true positive’’ and ‘‘true negative’’
results and then limit the analysis to specimens falling within
either category. Based on the criteria used, individuals who tested

Table 12. Negative-to-negative test concordance in community survey.

COMPARISON TEST (Numerator)
INDEX TEST
(Denominator) BM14

PANLFBC

BM14

827/880 (94%)

PanLF

827/1267 (65%)

Urine SXP

825/1344 (61%)

1401/1745 (80%)

ICT

1394/2178 (64%)

2376/3029 (78%)

URSXP

ICT

OG4C3

BLOOD

PCR*

825/867 (95%)

1394/1520 (91%)

1524/1610 (94%)

1404/1425 (98%)

1585/1592 (99%)

1401/1613 (86%)

2376/2544 (93%)

2432/2504 (97%)

2137/2155 (99%)

2512/2525 (99%)

2380/2654 (89%)
2380/3077 (77%)

2296/2470 (92%)

1595/1623 (98%)

2519/2549 (98%)

4903/5089 (96%)

3966/3984 (99%)

5149/5166 (99%)

Og4C3

1524/2320 (65%)

2432/3053 (79%)

2296/2932 (78%)

4903/5164 (94%)

Blood Smear

1404/2254 (62%)

2137/2873 (74%)

1595/2131 (74%)

3966/4364 (90%)

4051/4372 (92%)

4051/4062 (99%)

PCR*

1585/2574 (61%)

2512/3319 (75%)

2519/3336 (75%)

5149/5660 (90%)

5281/5716 (92%)

5281/5288 (99%)
4375/4392 (99%)

4375/4408 (99%)

Note: Fractions represent the number of negative results for each test (numerator) out of those that were negative by the index test (denominator). The results are of
the form: proportion (%). The number of negative index tests (denominator) changes by column because it only includes specimens with valid results by the
comparison test (numerator).
*Based on 10 ml blood specimen.
doi:10.1371/journal.pntd.0001479.t012
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Table 13. Sensitivity, specificity, and predictive values for antigen tests.

ICT

Og4C3

% (N)

95% Confidence Interval

% (N)

95% Confidence Interval

75.5 (94)

(66.8, 84.2)

87.2 (94)

(80.5, 94.0)

All Countriesa
Sensitivity
Specificity

92.5 (1647)

(91.2, 93.7)

94.6 (1647)

(93.5, 95.7)

Pos. Predictive Value

36.4 (195)

(29.7, 43.2)

48.0 (171)

(40.5, 55.4)

Neg. Predictive Value

98.5 (1546)

(97.9, 99.1)

99.2 (1570)

(98.8, 99.7)

Sensitivity

79.3 (29)

(64.6, 94.1)

93.1 (29)

(83.9, 100.0)

Specificity

92.3 (517)

(90.0, 94.6)

98.6 (517)

(97.6, 99.6)

French Polynesia

Pos. Predictive Value

36.5 (63)

(24.6, 48.4)

79.4 (34)

(65.8, 93)

Neg. Predictive Value

98.8 (483)

(97.8, 99.8)

99.6 (512)

(99.1, 100.0)

Sensitivity

61.1 (18)

(38.6, 83.6)

72.2 (18)

(51.5, 92.9)

Specificity

94.3 (754)

(92.6, 96.0)

91.6 (754)

(89.7, 93.6)

Ghana

Pos. Predictive Value

20.4 (54)

(9.6, 31.1)

17.1 (76)

(8.6, 25.6)

Neg. Predictive Value

99.0 (718)

(98.3, 99.7)

99.3 (696)

(98.7, 99.9)

Sensitivity

78.7 (47)

(67.0, 90.4)

89.4 (47)

(80.5, 98.2)

Specificity

89.1 (376)

(86.0, 92.3)

94.9 (376)

(92.7, 97.2)

Pos. Predictive Value

47.4 (78)

(36.4, 58.5)

68.9 (61)

(57.2, 80.5)

Neg. Predictive Value

97.1 (345)

(95.3, 98.9)

98.6 (362)

(97.4, 99.8)

Haiti

Definition of antigen test accuracy.
‘True Positive’: Blood Smear or PCR (+).
‘True Negative’: Blood Smear and PCR not (+); Bm14 and PanLF not (+).
a
Includes French Polynesia, Ghana and Haiti only; others excluded due to missing values for Bm14.
doi:10.1371/journal.pntd.0001479.t013

Finally, additional sources of error, common across many tests
and countries, stemmed from external issues. Logistical constraints
and risk of specimen contamination varied by country and is likely
to have caused some of the variance in test performance. The
possibility of reader error cannot be discounted.
Some of this study’s findings were unexpected and warrant
future research and analysis. Though the overall prevalence of
detection of antigen or antibody was similar for a given target, the
distributions of the test results suggest that they are performing
differently. Whether or not this difference is due to variability of
test performance or to the tests’ detecting different sub-populations
of positive individuals is hard to determine. For example, the
correlation between the ICT and Og4C3 antigen tests was much
lower than expected (phi coefficient 0.53); however both tests
identified similar overall prevalence of antigenemia. Part of the
discordance may be explained by the cut-point selected for the
Og4C3 test. Cut-points for Og4C3 were defined such that the only
‘‘true positive’’ specimens were those testing positive for
microfilariae (blood smear or PCR). This is likely to have limited
our ROC analysis to ‘‘strong positive’’ Og4C3 results (those with
higher unit values), as previous studies have found Og4C3 unit
values to be positively correlated with MF values [16–18].
Whether or not this biased our final cut-point is unclear. However,
the poor correlation may also suggest that the ICT and Og4C3
test are capturing different aspects of antigenemia. A more
controlled laboratory study would be needed to determine if this
were the case.
www.plosntds.org

Next Steps
The selection of the ICT as the best tool for establishing the
MDA stopping criteria is a significant programmatic advance.
However, further assessment is needed to develop the appropriate
guidelines for country program managers eager to decide if they
are ready to stop MDA. The selection of a diagnostic test is the
first step, but it is necessary to define a ‘‘threshold’’ of positive
results below which a country can safely discontinue its MDA
program. With the less-than-perfect sensitivity and specificity of
the diagnostic tools, such a threshold should be based on statistical
criteria that can account for the level of error in the measurement
with a 95% confidence interval [4]. Also integral to this assessment
is the method by which the population will be sampled, as both
sampling strategy and threshold will influence the sample size and
power of the surveys used to determine if the stopping MDA
criteria are met. Addressing these issues is the focus of ongoing
research efforts.
The global community has already made great progress on the
path to elimination of lymphatic filariasis. The selection of the ICT
test for defining the end-point of MDA, based on both the present
study and earlier observations permits the WHO to develop
appropriate guidelines that will allow many countries to move
closer to stopping their MDA programs. Future studies to evaluate
sampling strategies, ICT-based stopping thresholds, and long-term
consequences of the stopping decision will increasingly strengthen
the evidence base for the programmatic guidelines targeting LF
elimination.
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Table 14. Sensitivity, specificity, and predictive values for antibody tests.

PanLF

Rate

Bm14
95%
Confidence
Interval

Rate

Urine SXP
95% Confidence
Interval
Rate

95% Confidence
Interval

All Countries
Sensitivity

73.2 (82)

(63.5, 82.8)

81.1 (74)

(72.2, 90.0)

54.5 (77)

(43.4, 65.7)

Neg. Predictive Value

99.1 (2390)

(98.7, 99.5)

98.2 (790)

(97.3, 99.1)

97.7 (1522)

(96.9, 98.5)

French Polynesia
Sensitivity

76.9 (26)

(60.7, 93.1)

92.3 (26)

(82.1, 100)

92.3 (26)

(82.1, 102.6)

Neg. Predictive Value

99.1 (675)

(98.4, 99.8)

99.5 (438)

(98.9, 100)

99.6 (539)

(99.1, 100)

Sensitivity

–

–

50.0 (16)

(25.5, 74.5)

–

–

Neg. Predictive Value

–

–

98.8 (680)

(98.0, 99.6)

–

–

Ghana

Haiti
Sensitivity

70.8 (48)

(58.0, 83.7)

75.0 (48)

(62.8, 87.2)

31.9 (47)

(18.6, 45.2)

Neg. Predictive Value

96.8 (447)

(95.3, 98.5)

96.6 (336)

(94.7, 98.5)

94.2 (554)

(92.3, 96.2)

Sri Lanka
Sensitivity

66.7 (3)

(13.3, 100)

–

–

–

–

Neg. Predictive Value

99.9 (684)

(99.6, 100)

–

–

–

–

Sensitivity

50.0 (2)

(0, 100)

–

–

50.0 (2)

(0, 100)

Neg. Predictive Value

99.8 (548)

(99.5, 100)

–

–

99.7 (396)

(99.3, 100)

Tuvalu

Zanzibar
Sensitivity

–

–

–

–

42.9 (7)

(6.2, 79.5)

Neg. Predictive Value

–

–

–

–

99.3 (565)

(98.6, 100)

Definition of antibody test accuracy.
’True Positive’: Blood Smear or PCR (+).
‘True Negative’: Blood Smear and PCR not (+); ICT and Og4C3 not (+).
doi:10.1371/journal.pntd.0001479.t014
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Institut Louis Malardé, James Cook University, Noguchi Memorial
Institute for Medical Research, Smith College, Task Force for Global
Health, Washington University, and World Health Organization.

(DOC)
Table S1 A summary of the features and performance
of the seven diagnostic tests evaluated.
(DOC)
F Flow Chart S1 STARD flow chart detailing the method

for assessment of antibody diagnostic tests.
(DOCX)

Author Contributions

F Flow Chart S2 STARD flow chart detailing the method

for assessment of antigen diagnostic tests.
(DOCX)

Conceived and designed the experiments: MB PUF DK SJL EAO GJW
PL. Performed the experiments: MVEBdR DB PUF JG MI NIC HJ SJL
A-ML TSL WM KM NP CP RUR KR GJW SAW KW PL. Analyzed the
data: KG JT PL EAO KYW DK. Contributed reagents/materials/analysis
tools: GJW PUF PL MI WM. Wrote the paper: KG EAO PL KYW.

F low Chart S3 STARD flow chart detailing the method
for assessment of microfilariae diagnostic tests.
(DOCX)

References
4. Weil GJ, Ramzy RM (2007) Diagnostic tools for filariasis elimination programs.
Trends Parasitol 23: 78–82.
5. Bergquist R, Johansen MV, Utzinger J (2009) Diagnostic dilemmas in
helminthology: what tool to use and when? Trends in Parasitology 25:
151–156.
6. Global Alliance to Eliminate Lymphatic Filariasis (2006) Resolving the critical
challenges now facing the GPELF. Bill and Melinda Gates Grant. http://www.
filariasis.org/gates_foundation_grant.html.

1. Ottesen EA, Hooper PJ, Bradley M, Biswas G (2008) The global programme to
eliminate lymphatic filariasis: health impact after 8 years. PLoS Negl Trop Dis 2: e317.
2. World Health Organization (2008) Global programme to eliminate lymphatic
filariasis. Weekly Epidemiological Record 83: 333–348.
3. Ramzy RM, El Setouhy M, Helmy H, Ahmed ES, Abd Elaziz KM, et al. (2006)
Effect of yearly mass drug administration with diethylcarbamazine and
albendazole on bancroftian filariasis in Egypt: a comprehensive assessment.
Lancet 367: 992–999.

www.plosntds.org

11

January 2012 | Volume 6 | Issue 1 | e1479

Lymphatic Filariasis Diagnostic Tools Evaluation

13. Terhell AJ, Haarbrink M, Abadi K, Bronneberg DC, Tieleman MC, et al.
(1996) A filter paper technique for the detection of anti-filarial IgG4 in lymphatic
filariasis. Trans R Soc Trop Med Hyg 90: 196–198.
14. Joseph HM, Melrose W (2010) Applicability of the filter paper technique for
detection of antifilarial IgG4 antibodies using the Bm14 filariasis CELISA.
Journal of Parasitology Research 2010: 6.
15. Weil GJ, Curtis KC, Fischer PU, Won KY, Lammie PJ, et al. (2011) A
multicenter evaluation of a new antibody test kit for lymphatic filariasis
employing recombinant Brugia malayi antigen Bm-14. Acta Tropica 120 Suppl
1: S19–S22.
16. Chanteau S, Moulia-Pelat JP, Glaziou P, Nguyen NL, Luquiaud P, et al. (1994)
Og4C3 circulating antigen: a marker of infection and adult worm burden in
Wuchereria bancrofti filariasis. J Infect Dis 170: 247–250.
17. Rocha A, Braga C, Belem M, Carrera A, Aguiar-Santos A, et al. (2009)
Comparison of tests for the detection of circulating filarial antigen (Og4C3ELISA and AD12-ICT) and ultrasound in diagnosis of lymphatic filariasis in
individuals with microfilariae. Mem Inst Oswaldo Cruz 104: 621–625.
18. Wattal S, Dhariwal AC, Ralhan PK, Tripathi VC, Regu K, et al. (2007)
Evaluation of Og4C3 antigen ELISA as a tool for detection of bancroftian
filariasis under lymphatic filariasis elimination programme. Journal of Communicable Diseases 39: 75–84.

7. Standard Operating Procedures (2008) Gates Program: ‘‘Resolving Critical
Challenges Now Facing the Global Programme to Eliminate Lymphatic
Filariasis’’, Objective #1: Lymphatic Filariasis Support Center, The Taskforce
for Child Survival and Development. pp 1–55. http://www.filariasis.us/
resources.html.
8. Itoh M, Weerasooriya MV, Qiu G, Gunawardena NK, Anantaphruti MT, et al.
(2001) Sensitive and specific enzyme-linked immunosorbent assay for the
diagnosis of Wuchereria bancrofti infection in urine samples. American Journal
of Tropical Medicine and Hygiene 65: 362–365.
9. Rao RU, Atkinson LJ, Ramzy RM, Helmy H, Farid HA, et al. (2006) A realtime PCR-based assay for detection of Wuchereria bancrofti DNA in blood and
mosquitoes. Am J Trop Med Hyg 74: 826–832.
10. Banoo S, Bell D, Bossuyt P, Herring A, Mabey D, et al. (2006) Evaluation of
diagnostic tests for infectious diseases: general principles. Nat Rev Microbiol 4:
S20–32.
11. Hoti SL, Elango A, Radjame K, Yuvaraj J, Pani SP (2002) Detection of day
blood filarial antigens by Og4C3 ELISA test using filter paper samples. Natl
Med J India 15: 263–266.
12. Itoh M, Gunawardena NK, Qiu XG, Weerasooriya MV, Kimura E (1998) The
use of whole blood absorbed on filter paper to detect Wuchereria bancrofti
circulating antigen. Trans R Soc Trop Med Hyg 92: 513–515.

www.plosntds.org

12

January 2012 | Volume 6 | Issue 1 | e1479

